AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28854973
Drug: CCH (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCH (all doses)
Trial: 28854973
Drug: CCH 0.40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCH 0.40 mg and 0.60 mg
Trial: 23977864
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with blueberries (150 g on exercise days)
Trial: 21263103
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) program, 20 two-hour sessions over 1 year, median attendance 85%
Trial: 12755536
Drug: Simethicone-coated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone-coated cellulose (SCC) 800 mL
Trial: 12755536
Drug: Water 800
RxNorm normalized name: theophylline in dextrose 5 % in water 800 mg/L INTRAVEN INTRAVENOUS SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 800 mL
Trial: 7662242
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily, titrated to 100 mg if blood pressure uncontrolled after 6 weeks
Trial: 7662242
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once daily, titrated to 100 mg if blood pressure uncontrolled after 6 weeks
Trial: 28831250
Drug: Pulmonary Daoyin
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary Daoyin (PD) program, 3-month, ten times-weekly supervised rehabilitation
Trial: 16838873
Drug: Oral-B Indicator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B Indicator 40 toothbrush
Trial: 21782353
Drug: Prescription participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription participants (standard care)
Trial: 21782353
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Contingency and Prescription)
Trial: 18972123
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with paclitaxel (200 mg/m²) and cisplatin (100 mg/m²)
Trial: 18972123
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by radiotherapy (69.9 Gy in 5.5 weeks)
Trial: 9512672
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by radiotherapy
Trial: 16297751
Drug: Balanced inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced inhalation anesthesia (BAL)
Trial: 11980997
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (50.4 Gy/28 fractions)
Trial: 11980997
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation therapy (64.8 Gy/36 fractions)
Trial: 1663089
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole for a period of 6-8 weeks
Trial: 7078717
Drug: Neutral, emotionally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral, emotionally loaded, and 'mental task' stimuli; specific details on dosage and duration not available.
Trial: 31641767
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (ciprofloxacin)
Trial: 31641767
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (ceftriaxone)
Trial: 28118256
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy plus amitriptyline (CBT+A)
Trial: 26051874
Drug: Empagliflozin 50
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 50 mg alone for 5 days
Trial: 26051874
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg coadministered with pioglitazone 45 mg for 7 days
Trial: 26051874
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg coadministered with pioglitazone 45 mg for 7 days
Trial: 26051874
Drug: Empagliflozin 50
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 50 mg coadministered with pioglitazone 45 mg for 7 days
Trial: 26051874
Drug: Empagliflozin and
RxNorm normalized name: Empagliflozin and Linagliptin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin and pioglitazone combination treatment
Trial: 26051874
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg alone for 7 days
Trial: 26051874
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg coadministered with pioglitazone
Trial: 26051874
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg coadministered with pioglitazone
Trial: 26051874
Drug: Empagliflozin 50
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 50 mg coadministered with pioglitazone
Trial: 21735753
Drug: concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concomitant therapy
Trial: 16714852
Drug: Low-dose corticotropin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticotropin stimulation test with 1 microg of 1-24 ACTH intravenously
Trial: 16714852
Drug: Decreasing daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreasing daily equipotent doses of inhaled corticosteroids
Trial: 11310515
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination tablet (abacavir 300 mg, lamivudine 150 mg, zidovudine 300 mg taken twice/day)
Trial: 11310515
Drug: ABC‐COM (abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC‐COM (abacavir 300 mg plus lamivudine 150 mg and zidovudine 300 mg taken twice/day)
Trial: 11310515
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination tablet
Trial: 12470761
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control treatment
Trial: 27490921
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of hydrocortisone (0.4-0.6 mg/kg body weight)
Trial: 24861159
Drug: Phonological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonological therapy
Trial: 27260592
Drug: Articulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulation therapy
Trial: 15939139
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid plus carboplatin (standard administration)
Trial: 15939139
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid plus carboplatin (chronomodulated administration)
Trial: 15939139
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid (without carboplatin, standard administration)
Trial: 15939139
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-fluorouracil and folinic acid (without carboplatin, chronomodulated administration)
Trial: 11783243
Drug: Composite salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite salviae dropping pill (CSDP)
Trial: 1930035
Drug: 15 minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 minute oxytocin dose escalation
Trial: 1930035
Drug: 30 minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute oxytocin dose escalation
Trial: 3883697
Drug: Alaproclate 200
RxNorm normalized name: alaproclate
DrugBank: Alaproclate (DB13233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alaproclate 200 mg twice daily
Trial: 27428186
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with methotrexate, leflunomide, and hydroxychloroquine for up to 36 weeks
Trial: 27428186
Drug: Tapering DMARDs
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering DMARDs treatment after achieving remission (DAS28 ≤ 2.6) and low HAQ (≤ 0.5)
Trial: 15170905
Drug: Leflunomide monotherapy
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide monotherapy
Trial: 25414593
Drug: Combined psoas
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined psoas compartment-sciatic nerve block (PCSNB) using 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine and iliac crest block with 5 mL of the same solution.
Trial: 25414593
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anaesthesia (CSA) using 2.5 mg of isobaric bupivacaine 0.5%, with additional doses if sensory block did not reach T12.
Trial: 18399947
Drug: Silodosin 4
RxNorm normalized name: silodosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 4 mg twice daily for 3 days
Trial: 14522414
Drug: Enalapril pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril pre-treatment for 5 days
Trial: 14522414
Drug: Enalapril 2
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 2 hours before LPS infusion
Trial: 14522414
Drug: Placebo pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pre-treatment for 5 days
Trial: 1623802
Drug: T +
RxNorm normalized name: RE PreVit + DHA Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T + E (Terbutaline + Enalapril 10 mg)
Trial: 1623802
Drug: T +
RxNorm normalized name: RE PreVit + DHA Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T + S (Terbutaline + Spironolactone 100 mg)
Trial: 19450896
Drug: Low-dose interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interferon-alpha (IFN-alpha)
Trial: 16280432
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (300 mL)
Trial: 16280432
Drug: Water (control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control, 300 mL)
Trial: 16280432
Drug: Aspartame solution
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame solution (300 mL)
Trial: 16280432
Drug: Maltodextrin solution
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin solution (300 mL)
Trial: 9617982
Drug: Sibutramine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 20 mg
Trial: 12502668
Drug: Sibutramine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (both doses)
Trial: 8708979
Drug: Liquid Gaviscon
RxNorm normalized name: Gaviscon Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid Gaviscon (20 mL single dose)
Trial: 8708979
Drug: Algitec Suspension
RxNorm normalized name: Algitec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algitec Suspension (20 mL single dose)
Trial: 8708979
Drug: Algitec Suspension
RxNorm normalized name: Algitec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algitec Suspension
Trial: 1907317
Drug: APDT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APDT vaccine
Trial: 12677622
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of IV lidocaine (group L)
Trial: 12677622
Drug: 0.1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL/kg of IV isotonic saline (group C)
Trial: 8400327
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of tumour cyclic AMP binding proteins (> 8 pmol/mg cytosol protein)
Trial: 29669668
Drug: GSP301 (olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSP301 (olopatadine 665 μg - mometasone 50 μg)
Trial: 29669667
Drug: OLO-sponsor (olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLO-sponsor (olopatadine 665 μg)
Trial: 29669667
Drug: OLO (FDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLO (FDA approved olopatadine 665 μg)
Trial: 7811150
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of delayed action mexiletine
Trial: 3658285
Drug: 25-mg 17
RxNorm normalized name: ubidecarenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-mg 17 beta-estradiol pellets
Trial: 3658285
Drug: 50-mg 17
RxNorm normalized name: azathioprine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg 17 beta-estradiol pellets
Trial: 3658285
Drug: 25-mg and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-mg and 50-mg 17 beta-estradiol pellets
Trial: 31317627
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 75% oral sucrose (n = 20)
Trial: 29068099
Drug: Ciclosporin 50
RxNorm normalized name: Ciclosporin 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin 50 mg/mL solution for injection administered subcutaneously for 60 days, with initial doses ranging from 2.5 mg/kg once daily to every other day, and 5 mg/kg once daily to every other day.
Trial: 27484224
Drug: Iloprost (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (1 ng/kg/min) infusion for 48 hours
Trial: 25400947
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg orally every 12 hours for at least 2 days
Trial: 21168619
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of cyclosporine (blood cyclosporine C2, 800-1500 ng/mL) with MMF and standard doses of corticosteroids.
Trial: 21168619
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of cyclosporine (blood cyclosporine C2, 450-800 ng/mL) with MMF plus low doses of corticosteroids after induction 48 hours before surgery.
Trial: 16725396
Drug: Calcium-vitamin-D3-fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin-D3-fortified milk (1000 mg/day calcium and 800 IU/day vitamin D3)
Trial: 11040177
Drug: Methylprednisolone (0.75‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (0.75‐1 mg x kg(‐1) x day(‐1))
Trial: 11040177
Drug: Heparin (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (continuous infusion)
Trial: 1350734
Drug: Polyanhydrides as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyanhydrides as bioerodible polymers for drug delivery applications
Trial: 1350734
Drug: Polyanhydride-based drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyanhydride-based drug delivery treatment
Trial: 2981616
Drug: Levonantradol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonantradol (1 mg every 4 hours)
Trial: 2981616
Drug: Delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-9-tetrahydrocannabinol (THC) (15 mg every 4 hours)
Trial: 15753149
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 mcg l-selenomethionine)
Trial: 15753149
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg of racemic alpha-tocopheryl)
Trial: 11728984
Drug: EPO 50
RxNorm normalized name: Evening Primrose Oil 500 MG Oral Capsule, Liquid Filled [NUTR-EPO 500]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO 50 U/kg by subcutaneous injection 3 times per week
Trial: 11728984
Drug: EPO 50
RxNorm normalized name: Evening Primrose Oil 500 MG Oral Capsule, Liquid Filled [NUTR-EPO 500]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO 50 U/kg IV injection and AG 200 mg every other day by mouth
Trial: 11728984
Drug: EPO 50
RxNorm normalized name: Evening Primrose Oil 500 MG Oral Capsule, Liquid Filled [NUTR-EPO 500]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO 50 U/kg IV injection and placebo
Trial: 8150356
Drug: Pre-oxygenation with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-oxygenation with 4 litres/minute for five minutes before sedation, followed by continuous oxygen administration.
Trial: 27166718
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg of hCG, intravenously
Trial: 25429036
Drug: Immediate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Trial: 25429036
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Trial: 23692648
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention consisting of sessions concerning sports, parental involvement, individual counselling, lifestyle advice including dietary advice and cognitive behavioural therapy for 18 months.
Trial: 20673506
Drug: BSD2000 deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSD2000 deep hyperthermia combined with chemotherapy (paclitaxel: 135 mg/m2 ivdirp 3 h qd d1 + cisplatin: 20 mg/m2 ivdirp qd d1-5)
Trial: 20673506
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (paclitaxel and cisplatin)
Trial: 14661009
Drug: Candesartan 4
RxNorm normalized name: candesartan 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 4 mg/d
Trial: 14661009
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline treatment alone)
Trial: 2124180
Drug: Norethisterone enantate
RxNorm normalized name: Norethisterone enantate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone enantate 50 mg with estradiol valerate 5 mg (monthly injectable contraceptive)
Trial: 6153846
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline hydrochloride (Amphocycline)
Trial: 6153846
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline hydrochloride with 10% ethyl lactate solution applied twice daily
Trial: 6153846
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of ethyl lactate solution only
Trial: 31132664
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 40 mg/mL three times weekly (GA40)
Trial: 25929558
Drug: Guardian Laryngeal
RxNorm normalized name: Giardia lamblia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guardian Laryngeal Mask Airway (G‐LMA)
Trial: 21410839
Drug: MTZ in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ in situ gel (0.8% metronidazole), applied twice daily for 5 days
Trial: 21410839
Drug: Conventional vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional vaginal gel product, applied twice daily for 5 days
Trial: 19561037
Drug: Dexamethasone (12‐16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (12‐16 mg i.v. on day 1, 8 mg i.v. on day 2, and 4‐8 mg i.v. on day 3)
Trial: 17602038
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg intrathecal bupivacaine
Trial: 17602038
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg intrathecal bupivacaine
Trial: 15106360
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human follicle stimulating hormone (rhFSH) (Gonal‐F, Serono)